

MAY 2 4 2013

## 5. TRADITIONAL 510(K) SUMMARY

**DATE PREPARED:** 

May 23, 2013

SUBMITTED BY:

Advanced Orthopaedic Solutions, Inc.

386 Beech Avenue, Unit B6

Torrance, CA 90501 Phone: (310) 533-9966

**CONTACT PERSON:** 

Julie Glendrange

Advanced Orthopaedic Solutions, Inc.

386 Beech Avenue, Unit B6

Torrance, CA 90501 Phone: (310) 533-9966

**DEVICE NAME:** 

AOS Antegrade Femoral Nail System

**COMMON NAME:** 

Internal Fixation

**CLASSIFICATION:** 

Class II, 21 CFR 888.3020 Intramedullary Fixation

Rod

**DEVICE CODE:** 

**HSB** 

SUBSTANTIALLY

**EQUIVALENT DEVICE:** 

AOS Modular Femoral System (510(k): K012190,

Cleared September 24, 2001)

**DEVICE DESCRIPTION:** 

The AOS Antegrade Femoral Nail System consists of Titanium Alloy Rods, Screws and End Caps for femur

fracture fixation.

INDICATIONS FOR USE:

The AOS Antegrade Femoral Nail is intended for use in intramedullary fixation of fractures of the femur to include the following: Open and closed femoral fractures, Pseudoarthosis and correction osteotomy, Pathologic fractures, impending pathologic fractures, and tumor resections, Supracondylar fractures, including those with severe comminution and intra articular extension, ipsilateral femur fractures, bone lengthening, fractures proximal to a total knee arthroplasty or prosthesis, fractures distal to a hip ioint, nonunions and maluions, fractures resulting

from osteoprorosis.

SUBSTANTIAL EQUIVALENCE:

Information presented supports substantial equivalence of the AOS Antegrade Femoral Nail System to the predicate device. The proposed system has the same indications for use, is similar in shape and design, has the same fundamental technology and is made of the same material.

PRECLINICAL TESTING:

The AOS Antegrade Femoral Nail System was subjected to comparative mechanical testing per a test based on ASTM F384, as well as In Vitro testing of the accessory screws and components. A cadaver study was also done to assess various anatomical elements of the system. The results demonstrate that the AOS Antegrade Femoral Nails and accessories are substantially equivalent to the predicates.



Food and Drug Administration 10903 New Hampshire Avenue Document Control Center – WO66-G609 Silver Spring, MD 20993-0002

May 24, 2013

Advanced Orthopaedic Solutions, Incorporated % Ms. Julie Glendrange
Regulatory Specialist
386 Beech Avenue, Unit B6
Torrance, California 90501

Re: K123569

Trade/Device Name: AOS Antegrade Femoral Nail System

Regulation Number: 21 CFR 888.3020

Regulation Name: Intramedullary fixation rod

Regulatory Class: Class II Product Code: HSB Dated: April 23, 2013

Received: April 26, 2013

## Dear Ms. Glendrange:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <a href="http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm">http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm</a>.

For

Sincerely yours,

Erin Dkeith

Mark N. Melkerson
Director
Division of Orthopedic Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure



## 7. INDICATIONS FOR USE STATEMENT

Traditional 510(k) Premarket Notification Indication for Use Statement AOS Antegrade Femoral Nail System

510(k) Number (if known): K123569

Device Name: AOS Antegrade Femoral Nail System

## Indications for Use:

The AOS Antegrade Femoral Nail is intended for use in intramedullary fixation of fractures of the femur to include the following:

- Open and closed femoral fractures
- Pseudoarthrosis and correction osteotomy
- Pathologic fractures, impending pathologic fractures, and tumor resections
- Supracondylar fractures, including those with severe comminution and intraarticular extension
- Ipsilateral femur fractures
- Bone lengthening
- Fractures proximal to a total knee arthroplasty or prosthesis
- Fractures distal to a hip joint
- Nonunions and malunions
- · Fractures resulting from osteoporosis

Prescription Use: X	AND/OR	Over-The-Counter Use:
(Part 21 CFR 801 Subpart D)		(Part 21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NECESSARY)

Concurrence of CDRH, Office of Device Evaluation (ODE)

